Understanding and addressing vaccine hesitancy in the context of COVID-19: development of a digital intervention.


Journal

Public health
ISSN: 1476-5616
Titre abrégé: Public Health
Pays: Netherlands
ID NLM: 0376507

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 30 07 2021
revised: 29 09 2021
accepted: 10 10 2021
pubmed: 22 11 2021
medline: 15 12 2021
entrez: 21 11 2021
Statut: ppublish

Résumé

Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) was identified in late 2019, spreading to over 200 countries and resulting in almost two million deaths worldwide. The emergence of safe and effective vaccines provides a route out of the pandemic, with vaccination uptake of 75-90% needed to achieve population protection. Vaccine hesitancy is problematic for vaccine rollout; global reports suggest only 73% of the population may agree to being vaccinated. As a result, there is an urgent need to develop equitable and accessible interventions to address vaccine hesitancy at the population level. & Method: We report the development of a scalable digital intervention seeking to address COVID-19 vaccine hesitancy and enhance uptake of COVID-19 vaccines in the United Kingdom. Guided by motivational interviewing (MI) principles, the intervention includes a series of therapeutic dialogues addressing 10 key concerns of vaccine-hesitant individuals. Development of the intervention occurred linearly across four stages. During stage 1, we identified common reasons for COVID-19 vaccine hesitancy through analysis of existing survey data, a rapid systematic literature review, and public engagement workshops. Stage 2 comprised qualitative interviews with medical, immunological, and public health experts. Rapid content and thematic analysis of the data provided evidence-based responses to common vaccine concerns. Stage 3 involved the development of therapeutic dialogues through workshops with psychological and digital behaviour change experts. Dialogues were developed to address concerns using MI principles, including embracing resistance and supporting self-efficacy. Finally, stage 4 involved digitisation of the dialogues and pilot testing with members of the public. The digital intervention provides an evidence-based approach to addressing vaccine hesitancy through MI principles. The dialogues are user-selected, allowing exploration of relevant issues associated with hesitancy in a non-judgmental context. The text-based content and digital format allow for rapid modification to changing information and scalability for wider dissemination.

Identifiants

pubmed: 34801843
pii: S0033-3506(21)00412-1
doi: 10.1016/j.puhe.2021.10.006
pmc: PMC8520885
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
Vaccines 0

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

98-107

Subventions

Organisme : Medical Research Council
ID : MR/P008348/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

Références

Cochrane Database Syst Rev. 2020 Jan 17;1:CD011895
pubmed: 31978259
BMC Med. 2015 Sep 16;13:224
pubmed: 26377409
Expert Rev Vaccines. 2019 Nov;18(11):1167-1185
pubmed: 31791159
Lancet. 2020 Nov 21;396(10263):1614-1616
pubmed: 33159850
BMJ Open. 2020 Sep 15;10(9):e040620
pubmed: 32933965
Vaccine. 2020 Jan 16;38(3):433-443
pubmed: 31806532
Vaccine. 2015 Aug 14;33(34):4191-203
pubmed: 25896385
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Pan Afr Med J. 2021 Mar 02;38:230
pubmed: 34046135
J Med Internet Res. 2020 Jul 17;22(7):e14822
pubmed: 32520718
Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009748
pubmed: 22972147
Psychol Med. 2022 Oct;52(14):3127-3141
pubmed: 33305716
Vaccine. 2018 May 11;36(20):2751-2759
pubmed: 29661584
Ann Intern Med. 2021 Jun;174(6):882-885
pubmed: 33556267
Hum Vaccin Immunother. 2021 Jun 3;17(6):1612-1621
pubmed: 33242386
Brain Behav Immun. 2021 May;94:41-50
pubmed: 33713824
Ann Intern Med. 2020 Dec 15;173(12):964-973
pubmed: 32886525
Vaccines (Basel). 2020 Oct 03;8(4):
pubmed: 33022917
Early Hum Dev. 2020 Nov 12;:105259
pubmed: 33213968
Vaccines (Basel). 2020 Dec 30;9(1):
pubmed: 33396832
Vaccines (Basel). 2021 Jan 20;9(2):
pubmed: 33498395
Lancet Psychiatry. 2021 Feb;8(2):121-129
pubmed: 33306975
Implement Sci. 2019 Feb 1;14(1):11
pubmed: 30709368
Br J Health Psychol. 2020 Nov;25(4):1039-1054
pubmed: 32889759
Can Commun Dis Rep. 2020 Apr 02;46(4):93-97
pubmed: 32281992
J Med Internet Res. 2015 Jan 30;17(1):e30
pubmed: 25639757
Am J Prev Med. 2019 Oct;57(4):e125-e133
pubmed: 31471001

Auteurs

H Knight (H)

University of Nottingham, School of Medicine, Nottingham, UK.

R Jia (R)

University of Nottingham, School of Medicine, Nottingham, UK.

K Ayling (K)

University of Nottingham, School of Medicine, Nottingham, UK.

K Bradbury (K)

National Institute for Health Research (NIHR) ARC Wessex, UK; University of Southampton, Department of Psychology, Southampton, UK.

K Baker (K)

National Institute for Health Research (NIHR) ARC Wessex, UK.

T Chalder (T)

Kings College London, Department of Psychological Medicine, London, UK.

J R Morling (JR)

University of Nottingham, School of Medicine, Nottingham, UK; National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.

L Durrant (L)

University of Nottingham, School of Medicine, Nottingham, UK.

T Avery (T)

University of Nottingham, School of Medicine, Nottingham, UK.

J K Ball (JK)

University of Nottingham, School of Life Sciences, Nottingham, UK.

C Barker (C)

National Institute for Health Research (NIHR) ARC Wessex, UK.

R Bennett (R)

Rehab Studio LTD, London, UK.

T McKeever (T)

University of Nottingham, School of Medicine, Nottingham, UK.

K Vedhara (K)

University of Nottingham, School of Medicine, Nottingham, UK. Electronic address: kavita.vedhara@nottingham.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH